EMA (EU)
GUIDANCE FINAL
Concept paper on the revision of the guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances (EMA/CVMP/IWP/251947/2021)
Published: 6/26/2026Detected: 7/2/2026
Summary preview
Revises EMA/CVMP guidance for marketing-authorisation applications for immunological veterinary medicinal products under “exceptional circumstances,” aiming to reduce divergent interpretation and improve procedural…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
infectious_disease
rare_diseases
manufacturing
quality
clinical
safety
labeling
#exceptional circumstances
#immunological veterinary medicinal products
#veterinary vaccines
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026